Jardiance Does Not Increase Liver Enzymes—It Reduces Them
Jardiance (empagliflozin) does not increase liver enzymes; in fact, it significantly decreases them in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The FDA label contains no warnings about hepatotoxicity or liver enzyme elevation 1.
Evidence from FDA Drug Label
The official Jardiance prescribing information does not list elevated liver enzymes as an adverse effect. The documented laboratory abnormalities include:
- Increases in serum creatinine and decreases in eGFR (reversible hemodynamic changes)
- Increases in LDL cholesterol (2.3-6.5% dose-dependent)
- Increases in hematocrit (median 2.8%)
No hepatic safety signals or liver enzyme elevations are reported 1.
Evidence from Clinical Trials
Multiple recent meta-analyses demonstrate that empagliflozin improves liver enzyme profiles:
Liver Enzyme Reductions
- ALT reduction: -9.36 to -12.24 IU/L (statistically significant) 2, 3, 4
- AST reduction: -7.96 to -9.51 IU/L (statistically significant) 2, 3, 4
- GGT reduction: -14.92 to -25.5 IU/L (statistically significant) 2, 3
The most robust single study—a 2025 randomized controlled trial in 119 patients with type 2 diabetes and MASLD—showed dramatic improvements over 6 months 3:
- ALT decreased by 41.2 IU/L in the empagliflozin group vs. only 4.6 IU/L in controls (p < 0.001)
- AST decreased by 18.4 IU/L vs. 3.3 IU/L (p < 0.001)
- GGT decreased by 25.5 IU/L vs. 2.2 IU/L (p < 0.001)
Additional Hepatic Benefits
Beyond enzyme reduction, empagliflozin provides:
- Reduced liver fat content: -2.47% to -3.11% 5, 6
- Improved liver stiffness: -0.43 to -0.49 kPa 5, 6
- Improved FIB-4 fibrosis index 3
Clinical Context from Guidelines
The 2025 ADA Standards of Care note that GLP-1 receptor agonists improve MASLD "without worsening liver enzymes" 7. While this statement refers to GLP-1 RAs, the evidence for SGLT2 inhibitors like empagliflozin shows even more direct hepatoprotective effects with active enzyme reduction rather than just neutral effects.
Clinical Implications
If you observe liver enzyme elevation in a patient taking Jardiance, look for alternative causes:
- Concurrent medications (statins, antibiotics, supplements)
- Alcohol use
- Viral hepatitis
- Autoimmune hepatitis
- Biliary disease
- Progressive MASLD/MASH independent of treatment
The drug itself is hepatoprotective, not hepatotoxic. Empagliflozin's mechanism—reducing hepatic glucose production, decreasing visceral adiposity, and improving insulin sensitivity—explains its beneficial effects on liver inflammation and steatosis 2, 5, 6.